US Stock MarketDetailed Quotes
CYCC Cyclacel Pharmaceuticals
- 1.2199
- +0.0199+1.66%
Close Aug 23 16:00 ET
- 1.2000
- -0.0199-1.63%
Post 17:06 ET
2.41MMarket Cap-79P/E (TTM)
1.2300High1.1700Low32.91KVolume1.1800Open1.2000Pre Close39.60KTurnover1.87%Turnover RatioLossP/E (Static)1.97MShares11.343052wk High2.41P/B2.14MFloat Cap1.150052wk Low--Dividend TTM1.76MShs Float2141994.0840Historical High--Div YieldTTM5.00%Amplitude1.1500Historical Low1.2030Avg Price1Lot Size
Cyclacel Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -136.32%-3.08M | 92.96%-483K | 22.64%-16.11M | 24.36%-3.91M | 42.08%-4.04M | 31.85%-1.31M | -1.27%-6.86M | -12.34%-20.83M | -13.63%-5.17M | -12.21%-6.97M |
| Net income from continuing operations | 40.22%-3.26M | 49.24%-2.95M | -6.40%-22.56M | 28.95%-5.27M | -18.37%-6.03M | -19.08%-5.45M | -41.29%-5.8M | -14.85%-21.2M | -52.53%-7.42M | -2.17%-5.1M |
| Depreciation and amortization | -75.00%2K | -75.00%2K | -3.13%31K | 0.00%8K | 0.00%7K | 0.00%8K | -11.11%8K | -25.58%32K | 14.29%8K | -30.00%7K |
| Other non cash items | -14.29%-16K | 38.46%-16K | ---- | ---- | ---- | ---14K | -73.33%-26K | ---- | ---- | ---- |
| Change In working capital | -100.05%-2K | 257.92%2.27M | 523.22%4.94M | -44.42%1.03M | 168.69%1.56M | 65.72%3.79M | 52.65%-1.44M | 9.04%-1.17M | 46,275.00%1.86M | -46.13%-2.27M |
| -Change in prepaid assets | -74.00%1.18M | 263.70%2.02M | 224.52%4.71M | 239.26%1.35M | 103.97%75K | 41.34%4.52M | 70.09%-1.23M | 15.54%-3.78M | 46.96%-968K | 13.26%-1.89M |
| -Change in payables and accrued expense | -60.71%-1.18M | 223.30%254K | -88.51%296K | -110.78%-303K | 477.89%1.54M | 19.72%-733K | -118.99%-206K | -14.81%2.58M | 53.66%2.81M | -171.53%-407K |
| -Change in other current liabilities | ---- | ---- | -272.50%-69K | -227.27%-14K | ---- | ---- | ---- | -76.74%40K | 1,200.00%11K | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -136.32%-3.08M | 92.96%-483K | 22.64%-16.11M | 24.36%-3.91M | 42.08%-4.04M | 31.85%-1.31M | -1.27%-6.86M | -12.34%-20.83M | -13.63%-5.17M | -12.21%-6.97M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 0 | 14.29%-6K | 0 | 0 | 0 | -50.00%-6K | 74.07%-7K | 0 | 0 |
| Net PPE purchase and sale | --0 | --0 | 14.29%-6K | --0 | --0 | --0 | -50.00%-6K | 74.07%-7K | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | --0 | 14.29%-6K | --0 | --0 | --0 | -50.00%-6K | 74.07%-7K | --0 | --0 |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 12,431.37%6.29M | -58.00%-79K | -71.71%848K | 2,278.57%999K | -103.26%-50K | -103.46%-51K | 0.00%-50K | -86.21%3M | -95.26%42K | -47.25%1.53M |
| Net common stock issuance | ---- | ---- | -67.21%1.05M | 1,040.22%1.05M | --0 | ---- | ---- | -81.58%3.2M | 102.53%92K | -46.45%1.58M |
| Cash dividends paid | --0 | --0 | 0.00%-201K | 0.00%-50K | 0.00%-50K | 0.00%-51K | 0.00%-50K | 0.00%-201K | 0.00%-50K | 0.00%-50K |
| Net other financing activities | ---- | ---79K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 12,431.37%6.29M | -58.00%-79K | -71.71%848K | 2,278.57%999K | -103.26%-50K | -103.46%-51K | 0.00%-50K | -86.21%3M | -95.26%42K | -47.25%1.53M |
| Net cash flow | ||||||||||
| Beginning cash position | -75.53%2.8M | -81.59%3.38M | -49.82%18.35M | -74.93%5.94M | -65.04%10.16M | -61.42%11.44M | -49.82%18.35M | 9.44%36.56M | -41.06%23.71M | -33.37%29.08M |
| Current changes in cash | 336.36%3.21M | 91.88%-562K | 14.39%-15.27M | 43.22%-2.91M | 24.83%-4.09M | -205.41%-1.36M | -1.29%-6.92M | -662.65%-17.84M | -39.93%-5.13M | -63.98%-5.44M |
| Effect of exchange rate changes | -103.53%-3K | -357.14%-18K | 180.16%303K | 247.44%345K | -306.15%-134K | 172.03%85K | 107.69%7K | -2,123.53%-378K | -5,950.00%-234K | 161.90%65K |
| End cash Position | -40.97%6M | -75.53%2.8M | -81.59%3.38M | -81.59%3.38M | -74.93%5.94M | -65.04%10.16M | -61.42%11.44M | -49.82%18.35M | -49.82%18.35M | -41.06%23.71M |
| Free cash flow | -136.32%-3.08M | 92.97%-483K | 22.64%-16.12M | 24.36%-3.91M | 42.08%-4.04M | 31.96%-1.31M | -1.30%-6.87M | -12.21%-20.83M | -13.58%-5.17M | -12.04%-6.97M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg